Blockade of nitric oxide formation enhances thermal and behavioral responses in rats during turpentine abscess.
OBJECTIVE
The purpose of this study was to investigate the role of nitric oxide (NO) during the development of fever and other symptoms of sickness behavior (i.e. anorexia, cachexia) in response to localized tissue inflammation caused by injection of turpentine in freely moving biotelemetered rats.


METHODS
To determine the role of NO in turpentine-induced fever, we injected the NO synthase (NOS) inhibitor N(omega)-nitro-L-arginine methyl ester (L-NAME) intraperitoneally simultaneously or 5 h after turpentine injection.


RESULTS
Rats responded with fever to intramuscular injection of 20 microl of turpentine that commenced 6 h after injection and reached peak values 11 h after injection. Although turpentine did not significantly alter food and water intake, it caused a drop in body weight. Rats injected with turpentine and treated with L-NAME responded with a substantial rise in fever, independently of the time of L-NAME injection. The rise in body temperature (T(b)) due to turpentine injection began slightly sooner and reached the maximal T(b) value faster in rats treated with L-NAME than in the ones treated with saline (control for L-NAME). The enhanced decrease in food and water intake in rats treated with a combination of L-NAME and turpentine was also observed. As a result, L-NAME-injected rats responded with a profound drop in body mass due to turpentine, independently of the time of L-NAME injection. L-NAME alone did not affect food and water intake, but slightly suppressed the gain of body mass.


CONCLUSIONS
These results indirectly indicate that NO is involved in pyrogenic and behavioral responses in rats during turpentine abscess.
Department of Physiology, Ludwik Rydygier Medical University, Bydgoszcz, Poland. dareks@aci.amb.bydgoszcz.pl
D
D
Soszynski
D000818:Animals; D001831:Body Temperature / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D004326:Drinking / Q000187:drug effects*; D004435:Eating / Q000187:drug effects*; D005334:Fever / Q000139:chemically induced* / Q000201:enzymology / Q000503:physiopathology; D007249:Inflammation / Q000139:chemically induced / Q000201:enzymology / Q000503:physiopathology; D007273:Injections, Intramuscular; D007274:Injections, Intraperitoneal; D008297:Male; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009569:Nitric Oxide / Q000037:antagonists & inhibitors / Q000378:metabolism*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D014425:Turpentine / Q000008:administration & dosage / Q000494:pharmacology*
D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D019331:NG-Nitroarginine Methyl Ester; D014425:Turpentine